Download PDF
Dtsch Med Wochenschr 2013; 138(28/29): 1478-1482
DOI: 10.1055/s-0033-1343222
Prinzip & Perspektive | Review article
Onkologie, Immunologie
© Georg Thieme Verlag KG Stuttgart · New York

Immunmodulation durch Tryptophanstoffwechsel

Klinische Relevanz für Autoimmun- und TumorerkrankungenImmune modulation by tryptophan metabolism: relevance for autoimmune and tumor diseases
M. Platten
1   Abteilung Neuroonkologie, Nationales Zentrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg, sowie KKE Neuroimmunologie und Hirntumorimmunologie, Deutsches Krebsforschungszentrum Heidelberg
,
W. Wick
1   Abteilung Neuroonkologie, Nationales Zentrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg, sowie KKE Neuroimmunologie und Hirntumorimmunologie, Deutsches Krebsforschungszentrum Heidelberg
,
C. Opitz
1   Abteilung Neuroonkologie, Nationales Zentrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg, sowie KKE Neuroimmunologie und Hirntumorimmunologie, Deutsches Krebsforschungszentrum Heidelberg
› Author Affiliations
Further Information

Publication History

16 October 2012

06 February 2013

Publication Date:
02 July 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Tryptophan - Multiple Sklerose - Glioblastom - Ernährung

Keywords

tryptophan - multiple sclerosis - glioblastome - nutrition
 

  • Literatur

  • 1 Balachandran VP, Cavnar MJ, Zeng S et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17: 1094-1100
    CrossrefPubMedGoogle Scholar
  • 2 Esser C, Rannug A, Stockinger B. The aryl hydrocarbon receptor in immunity. Trends Immunol 2009; 30: 447-454
    CrossrefPubMedGoogle Scholar
  • 3 Fallarino F, Grohmann U, Puccetti P. Indoleamine 2,3-dioxygenase: From catalyst to signaling function. Eur J Immunol 2012; 42: 1932-1937
    CrossrefPubMedGoogle Scholar
  • 4 NICE. Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) 2012; 4: 734-745
    PubMedGoogle Scholar
  • 5 Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193
    CrossrefPubMedGoogle Scholar
  • 6 Opitz CA, Litzenburger UM, Sahm F et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478: 197-203
    CrossrefPubMedGoogle Scholar
  • 7 Opitz CA, Wick W, Steinman L et al. Tryptophan degradation in autoimmune diseases. Cell Mol Life Sci 2007; 64: 2542-2563
    CrossrefPubMedGoogle Scholar
  • 8 Peng W, Robertson L, Gallinetti J et al. Surgical stress resistance induced by single amino acid deprivation requires Gcn2 in mice. Sci Transl Med 2012; 4: 118ra111
    PubMedGoogle Scholar
  • 9 Pilotte L, Larrieu P, Stroobant V et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 2012; 109: 2497-2502
    CrossrefPubMedGoogle Scholar
  • 10 Platten M, Ho PP, Youssef S et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005; 310: 850-855
    CrossrefPubMedGoogle Scholar
  • 11 Platten M, Litzenburger U, Wick W. The aryl hydrocarbon receptor in tumor immunity. Oncoimmunology 2012; 1: 396-397
    CrossrefPubMedGoogle Scholar
  • 12 Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27: 3889-3900
    CrossrefPubMedGoogle Scholar
  • 13 Schwarcz R, Bruno JP, Muchowski PJ et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-477
    CrossrefPubMedGoogle Scholar
  • 14 Zwilling D, Huang SY et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011; 145: 863-874
    CrossrefPubMedGoogle Scholar